The standard changed.
Biological credibility became the baseline.

Longevity science moved into skincare.
Commercial momentum moved faster than validation.

Brands need decision-grade signal.
Researchers need skin-relevant translation.
We build the evidence layer between them.

Not a trend.
A structural shift.

This is Évoli.

Independent evidence for next-generation skincare -
for the brands building it, and the researchers discovering it

Who are you building for?

I represent a brand I'm a researcher
For Researchers

Your molecule
needs a market.

Next-generation molecules are finding new applications in skincare - and they need a translation pathway. Évoli helps researchers take novel actives from bench findings to skin-relevant validation, commercial dossiers, and industry adoption.

The disconnect

You designed your study to understand a mechanism.
Brands need to know whether it translates to human skin - and what the evidence can responsibly support.

Cellular senescence, mitochondrial dysfunction, epigenetic drift - these pathways are highly relevant to skin biology. The missing layer is a decision-grade translation from novel longevity molecules to skin-relevant validation.

That's what we provide.

The Translation Gap

Four walls
between you and market.

Mechanism ≠ product evidence

Your study establishes biological truth. Brands still need skin-relevant validation: appropriate models, measurable endpoints, conservative interpretation, and documentation that stands up to R&D, scientific affairs, and regulatory scrutiny.

Cosmetic adoption has its own constraints

Therapeutic mechanism data doesn't always translate cleanly to topical delivery, cosmetic positioning, or allowable claims. Without that alignment, commercialization can slow - regardless of how compelling the mechanism is.

Tech transfer rarely speaks skincare

Biotech and pharma licensing is a well-worn path. Cosmetic ingredient adoption has different buyers, standards, and timelines. The gap between a strong molecule and a brand decision often lives here.

Demand signal is hard to read

Not every longevity pathway is equally prioritized by brands at the same moment. Knowing which questions decision-makers need answered - and how to package evidence responsibly - often determines whether interest converts into a program.

How it works

One end-to-end engagement.

01
Skin Validation Design
Model choice, endpoints, controls, and go/no-go criteria - built for conservative interpretation.
02
Decision-Grade Evidence Pilot
A focused pilot on human-relevant skin models with biomarker readouts - built to surface early signal and stop weak ideas early.
03
Evidence Package
Protocol summary, readouts, limitations, and a substantiation-style narrative that can survive internal scrutiny.
04
Commercial Readiness
Topical feasibility, what evidence is needed next, and what can (and cannot) be claimed from the data.
Why come in early

Help set the standard
before someone else does.

The evidence infrastructure for longevity skincare is being built right now. Researchers who come in early don't just reach market faster - they shape which endpoints matter and what the industry reference standard looks like.

Tell us where you are.
We'll map the fastest, defensible path forward.

Start the conversation
For Brands

The standard is being set.
Be the one setting it.

Next-generation actives are moving into skincare faster than validation can keep up. Évoli helps skincare R&D teams evaluate them through decision-grade pilot studies, using human-relevant models and biomarker readouts. Early signal, clearer comparisons, dossier-ready outputs.

The market gap

"Longevity cosmeceutical" has no peer-reviewed definition. No regulatory recognition. No standardized evidence framework.

Cellular senescence, mitochondrial dysfunction, epigenetic drift - the biology is compelling. The missing layer is repeatable, decision-grade evidence on consistent endpoints. We're building it - and the brands that move now will define the standard.

The Barriers

Four problems
most brands don't name.

No comparable data

Every supplier, startup, and paper uses different endpoints. You can't compare them. Ingredient decisions become internal debates - and the wrong bets are costly.

Studies are expensive to run

Most brands can't run enough to build a real intelligence picture. The brands that can are larger than you - and they're moving fast.

Longevity washing is a real risk

Retailers, press, and regulators are tightening. Brands citing supplier data as proof are accumulating liability they haven't priced in yet.

Novel molecules are hard to source (and harder to vet)

The most interesting longevity actives often start in academia or therapeutic programs - outside the traditional supplier ecosystem. Brands hear about them late, with little skin-specific validation to act on.

What we deliver

Not a study.
A decision.

Comparative intelligence

Not just whether your active works - how it ranks against the field. Context that changes what you launch. Benchmark reports are shared across brands - making comparable data accessible at a fraction of what a custom study costs.

Claim-ready output

Every engagement delivers a dossier-ready evidence package - formatted for regulators, retail buyers, and press. Not a raw lab report.

True independence

No supplier relationships. No brand conflicts. Our validation is credible because we have nothing to gain from a particular result.

Access to novel compounds

The most interesting longevity actives don't come through traditional supplier channels. We connect brands with validated molecules from academic and therapeutic pipelines - before they reach the market.

Engagement options

Three ways in.

Evidence Pilots

A bespoke study designed around your pathway and commercial goals - with interpretation that connects results directly to claims your team can use.

Get in touch

Benchmark Reports

Comparable efficacy data across a category of actives, pre-sold across brands to share cost. Commissioning partners get early access and "Validated by Évoli" co-branding rights.

Get in touch

Membership

Ongoing access to the benchmark database and quarterly intelligence briefings on the longevity ingredient pipeline.

Launching soon

Book a discovery call. We'll map the right evidence path for where you are.

Book a discovery call
About Évoli

Science you can
stake your brand on.

We founded Évoli because the skincare industry needed something it didn’t have: a truly independent research partner that speaks both the language of biology and the language of business.

Why it matters now

“Longevity washing” is already becoming a liability.

As longevity claims proliferate, brands without rigorous independent evidence face growing scrutiny. Évoli is the credibility layer between cutting-edge biology and defensible market claims - for both the brands bringing actives to market, and the researchers who discovered them.

“The Morningstar for skincare biology.”

The only independent platform benchmarking biological efficacy across longevity actives - so brands and researchers have a common, trusted standard.

The longevity era is bringing extraordinary science into skincare - cellular senescence, mitochondrial function, epigenetic reprogramming. But access to compelling ingredients is only half the challenge. The harder part is translating biological data into decisions your team can act on and claims your brand can stand behind.

Évoli is that translation layer. We work with the brands commercializing next-generation actives, and the researchers discovering them - bridging bench science to brand-ready evidence at every stage of the pipeline.

No conflicts. No black boxes. Just rigorous, independent science - built to last.

Chloe Wang - Founder & CEO, Évoli
Founder & CEO

Chloe Wang

chloe@evolibio.com

Background

10+ years building and scaling global products across Apple, Sephora (LVMH), Twitter, and Grab. Former Head of Innovation at Sephora, bridging ingredient science with consumer strategy and go-to-market execution.

Our credibility foundation

Why work with Évoli

Scientific Advisory Board

Leading researchers from top universities review our study designs and ensure our work meets academic-grade standards.

Transparent Methodology

We document model choice, endpoint rationale, controls, and assumptions - so results are interpretable, auditable, and built to stand up to scrutiny.

Top-Tier CRO Partners

We partner with specialist labs and CROs using human-relevant 3D skin models, ex vivo tissue options, and advanced biomarker readouts - designed for comparable, decision-grade evidence.

Independent = Unbiased

No supplier relationships. No brand conflicts. Our only obligation is to accurate science.

Scientific Advisory Board

Advisors who shape the research

Monica Isgut - Scientific Advisor, Evoli

Monica Isgut, PhD

Scientific Advisor

12+ years of combined experience as a biologist, AI data scientist, and strategist with prior work studying senescence, cellular resilience, and translational biomarker development, helping bridge advanced aging biology with decision-grade, capital-efficient R&D in human-relevant models.

Taihao Quan

Taihao Quan, MD, PhD

Scientific Advisor

Research Professor of Dermatology at the University of Michigan. 30+ years studying collagen homeostasis, extracellular matrix remodeling, and the molecular biology of skin aging. 65+ peer-reviewed papers, NIH-funded. One of the field's most published voices on how skin ages at the cellular level.

Research focus areas

Biological pathways we study

Cellular Senescence
Mitochondrial Function
Extracellular Matrix Integrity
Oxidative Stress Resilience
Skin Barrier & Inflammation
Epigenetic Stability
Engagement

A two-sided platform
for longevity science.

We serve both sides of the ecosystem - brands that need biological evidence to validate their claims, and researchers with novel molecules ready for commercial translation.

For Brands

Mid-sized brands entering longevity without internal R&D capabilities. We translate biological results into defensible claims, competitive context, and dossier-ready evidence - so your team can act with confidence.

Evidence Pilots

Rapid, decision-grade studies designed around your pathway and endpoints. Includes CRO selection, study design, and strategic interpretation.

Get in touch

Benchmark Reports

Comparable biological efficacy data across emerging actives in a category. Pre-sold to multiple brands to distribute cost - with early-access and co-branding rights for commissioning partners.

Get in touch

Membership

Ongoing access to benchmarks + quarterly research briefings on longevity biology trends.

Launching soon
For Researchers

You’ve identified a novel longevity molecule. We help you validate it for skin, position it commercially, and connect it with the brands that should be licensing it.

Skin-Specific Study Design

Design the minimum viable set of skin aging endpoints to demonstrate cosmetic potential - translating your mechanism-level findings into the language skincare brands understand.

Get in touch

Commercial Dossier & Brand Matchmaking

Package your validation data into the format R&D and regulatory teams expect, then facilitate introductions with brands actively building their longevity pipeline.

Get in touch

IP & Market Positioning

Guidance on method-of-use patent strategy for cosmetic applications, and market context on which biological pathways are commercially most relevant right now.

Get in touch
What to expect

From first conversation
to validated evidence

01
Discovery Call
Align on pathway, endpoints, and constraints.
02
Study Plan
Protocol, model selection, and timeline.
03
Execution
Partner lab kickoff and run oversight.
04
Delivery
Data package + dossier-ready evidence summary.
Évoli Insights

Longevity intelligence.

Research distilled. Trends decoded. The science your brand needs to stay ahead in the longevity era.

01
Cellular Biology
Why Cellular Senescence Is the Most Important Concept in Modern Skincare
Zombie cells are accumulating in your skin right now. Here's what that means for aging - and what ingredients actually address it.
→
02
Mitochondria
Mitochondrial Function and Skin Energy: The Missing Link in Anti-Aging Claims
The energy crisis happening in aging skin cells - and why your formula needs to speak to it.
→
03
Industry
The Claim Credibility Gap: Why "Clinically Proven" Isn't Enough Anymore
Longevity consumers are more scientifically literate than ever. Here's what evidence standards now look like.
→
04
ECM
Extracellular Matrix Integrity: The Structural Story Behind Skin Firmness
Collagen is just one piece of the ECM puzzle. A deep dive into fibronectin, elastin, and the matrix metalloproteinases reshaping skincare R&D.
→
05
Barrier Science
The Skin Barrier Is Not Just a Buzzword: What the Science Actually Says
From ceramide ratios to tight-junction proteins - what "barrier support" means in evidence terms, and how to measure it.
→
06
Research Design
What Makes a Skincare Study Credible? A Brand's Guide to Research Quality
Not all studies are equal. A practical framework for evaluating the research behind ingredient claims.
→
Get in touch

Let's build your
evidence strategy.

Whether you're validating a first ingredient or building a long-term research pipeline - book a call and we'll design the right path forward.

Email
chloe@evolibio.com
Based in
San Francisco, CA
Send message